Kinesis Pharma, a leading partner in drug development that integrates Chemistry, Manufacturing & Control, preclinical, clinical, regulatory, quality and Project Management, is pleased to announce the start of Alliance4U. This new collaborative initiative focuses on adding value to academic start ups, spin offs and small biotech companies by moving drug candidates forward to the next stage in development.
The initiative comprises 3 types of projects: Target Product Profile, Gap Analysis and Drug Development Plan. Kinesis offers to bridge financial and other business challenges to help companies moving to the next phase. Kinesis invites startups, spin off companies and small biotech to apply for this collaborative initiative and benefit from access to a team of experienced professionals with regulatory and industry experience.
Kees Groen, CEO Kinesis Pharma: The combined expertise within Kinesis will be a valuable source for biotech companies to upgrade the quality of their business proposals to potential investors. Early feed-back on this initiative has been extremely positive.